Clinical trial Phase 1/2 Interventional Ages 18 to 65

LOC-R01 Study of Lenalidomide and Ibrutinib in Association With Rituximab-Methotrexate Procarbazine Vincristin (R-MPV)

Run by Institut Curie · NCT04446962 · Data updated 2026-11-12

Fully enrolled, still running. This study is not taking new participants. Its registered completion date is 2035-02-02.

This study is to improve the first-line induction chemotherapy, by combining either Ibrutinib, or Lenalidomide, to a conventional immuno- chemotherapy of R-MPV type (Rituximab-Methotrexate-Procarbazine-Vincristine). This is a randomized Phase II trial, preceded by a dose escalation phase Ib. The objective of the phase Ib is to rule out any limiting toxicity of the new treatment associations, and to determine the recommended dose of Lenalidomide and Ibrutinib to be used in the phase II. In the phase II study, patients will receive 4 cycles of R-MPV + Lenalidomide or 4 cycles of R-MPV + Ibrutini…

Quick facts

PhasePhase 1/2
Study typeInterventional
Ages18 Years to 65 Years
SexAll
Enrollment118 (estimated)
SponsorInstitut Curie
Academic / other
Drugs / interventionsLenalidomide, Ibrutinib
Locations28 sites (France)
Trial IDNCT04446962 on ClinicalTrials.gov

What this trial studies

The objective of this proposal is to test the feasibility and efficacy of two targeted induction chemotherapies obtained by adding either Lenalidomide or Ibrutinib to a standard Rituximab-High Dose (HD) Methotrexate (MTX) based induction chemotherapy regimen. The R-MPV regimen is chosen as the backbone chemotherapy because of its wide use with robust reproducible results and a good and manageable toxicity profile

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Newly diagnosed Primary Central Nervous System Lymphoma (PCNSL).
2. a) Aged between 18 and 60 (\>18 and \< 60) - phase IB b) Aged between 18 and 65 (≥ 18 and ≤ 65) - phase II.
3. Histological confirmed diagnosis of Primary central nervous system lymphoma of Diffuse Large B-Cell Lymphomas (DLBCL) type OR patients with a measurable typical cerebral lesion on MRI with a diagnosis made by cytology and/or by flow cytometry on the vitreous or on the cerebral spinal fluid.
4. Measurable lesion on MRI with gadolinium enhancement.
5. Adequate hematological, renal and hepatic function (Laboratory Parameters realized within 14 days before inclusion):

   1. Absolute neutrophil count (ANC) \>1000/mm3
   2. Platelets \> 100,000/mm3 independent of transfusion support
   3. Alanine aminotransferase and aspartate aminotransferase ≤ 3 x Upper Limit of Normal (ULN)
   4. Total bilirubin ≤ 1.5 x ULN unless bilirubin rise is due to Gilbert's syndrome or of non-hepatic origin
   5. Estimated Glomerular Filtration Rate ≥ 60 mL/min/1.73m2.
6. Able to swallow capsules.
7. Karnofsky performance status: 40-100% for the phase IB and no restriction on the KPS for the phase II.
8. Able to understand teratogenic risks of the Lenalidomide and Ibrutinib. Patient must be able to understand and fulfill the Lenalidomide Pregnancy Prevention Plan requirements. This plan may be accepted by the person of confidence in case of impaired cognitive status of the patient.
9. Women of childbearing potential (WCBP)\* and men who are sexually active must be practicing a highly effective method\*\* of birth control. Women should avoid a pregnancy while taking treatment by Lenalidomide or Ibrutinib and for up to 1 month after ending treatment. Men must agree to not to father a child or donate sperm during treatment by Lenalidomide or Ibrutinib and up to 3 months after the last dose of study drug.
10. Women of childbearing potential (WCBP)\* must have a negative serum (beta-human chorionic gonadotropin \[B-hCG\]) or urine pregnancy test at inclusion.
11. Signed informed consent, which could be signed by a person on confidence in case the neurologic status of the patient does not allow him to understand and/or to sign.

Exclusion Criteria:

1. Histology other than DLBCL.
2. Positive HIV serology.
3. Active viral infection with Hepatitis B or C virus.
4. Preexisting immunodeficiency and/or organ transplant recipient.
5. Isolated Central Nervous System (CNS) relapse of systemic Non-Hodgkin's Lymphoma.
6. Prior treatment for PCNSL (except corticosteroids).
7. Isolated primary vitreo-retinal lymphoma.
8. Major surgery, within 4 weeks prior to the first dose of study drug. Stereotactic biopsy and vitrectomy are not considered major surgery.
9. History of stroke or intracranial hemorrhage (except minor post biopsy hemorrhage) within 6 months prior to inclusion.
10. Requires anticoagulation with warfarin or equivalent vitamin K antagonists.
11. Requires treatment with strong CYP3A4 inhibitors.
12. Pregnancy or lactation.
13. Clinically significant cardiovascular disease.
14. Any other active malignancy, except basocellular carcinoma and non-invasive cervix cancer.
15. Inclusion in another experimental anti-cancer drug therapy.
16. No social security affiliation.
17. Persons under legal protection.

Where it's running

  • CHU Amiens
    Amiens, France
  • CHU Angers
    Angers, France
  • CH côte Basque
    Bayonne, France
  • CHU Besançon
    Besançon, France
  • Institut Bergonié
    Bordeaux, France
  • CHU Caen
    Caen, France
Show 22 more locations
  • CHU Clermont-Ferrand
    Clermont-Ferrand, France
  • CH Colmar
    Colmar, France
  • CHU Créteil
    Créteil, France
  • CHU Dijon
    Dijon, France
  • CHU Grenoble
    Grenoble, France
  • CHRU Lille
    Lille, France
  • CHU Limoges
    Limoges, France
  • CHU Lyon
    Lyon, France
  • CHU La Timone Marseille
    Marseille, France
  • CHU Nancy
    Nancy, France
  • CHU Nantes
    Nantes, France
  • Centre Lacassagne
    Nice, France
  • CHU Nîmes - Carémeau
    Nîmes, France
  • Institut Curie
    Paris, France
  • Hôpital Cochin
    Paris, France
  • CHU Pitié-Salpêtrière
    Paris, France
  • CHU Poitiers
    Poitiers, France
  • CHU Rennes
    Rennes, France
  • Centre Henri Becquerel
    Rouen, France
  • CHU Strasbourg-Hôpital Hautepierre
    Strasbourg, France
  • IUCT -Oncopole
    Toulouse, France
  • CHU Tours
    Tours, France

Study contacts

  • Principal investigator: Steven LE GOUILL, PhD — Institut Curie

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

  • Ibrutinib and Venetoclax in CLL/SLL: Long-Term Outcomes After Frontline CAPTIVATE

    This study follows people with CLL or SLL who previously received the ibrutinib plus venetoclax combination in CAPTIVATE to see how they do over time and what treatments they need if the disease returns.

    Recruiting European Research Initiative on CLL · Milan · NCT07774390

  • Ibrutinib and Venetoclax for Chronic Lymphocytic Leukemia in Real-World Care

    This study tests whether a fixed-duration Ibrutinib plus Venetoclax treatment works in real-world care for people with CLL or SLL.

    Recruiting Janssen Research & Development, LLC · Bucharest · NCT07602088

  • Epcoritamab plus ibrutinib for central nervous system lymphoma

    This trial tests whether combining epcoritamab and ibrutinib is safe and tolerable for adults with relapsed or refractory primary or secondary central nervous system lymphoma.

    Recruiting at 8 sites Phase 1 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 7 other locations · NCT07082868

  • Using acalabrutinib to treat chronic lymphocytic leukemia and small lymphocytic lymphoma

    This study is testing if acalabrutinib can safely treat people with chronic lymphocytic leukemia or small lymphocytic lymphoma who can't tolerate ibrutinib, while also keeping an eye on their heart health.

    Recruiting Phase 2 Ohio State University Comprehensive Cancer Center · Columbus, Ohio · NCT06757647

  • ViPOR combination therapy for relapsed or refractory aggressive B‑cell lymphoma

    This treatment will try a five‑drug targeted combination called ViPOR (venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide) in adults whose aggressive B‑cell lymphoma has relapsed or not responded to prior therapy, focusing on specific genetic subtypes like CD10‑negative DLBCL and high‑grade B‑cell lympho

    Recruiting at 99 sites Phase 2 National Cancer Institute (NCI) · Tucson, Arizona and 114 other locations · NCT06649812

  • Combination treatment of epcoritamab and ibrutinib for aggressive B-cell lymphoma

    This study is testing a new combination of two treatments, epcoritamab and ibrutinib, to see if they can help people with aggressive B-cell lymphoma that hasn't responded to other therapies.

    Recruiting at 3 sites Phase 1/2 Ohio State University Comprehensive Cancer Center · Minneapolis, Minnesota and 2 other locations · NCT06536049

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-16 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.